99- Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy: effects on
the neonatal immune system. Acta Neurol Scand. 2012;127(1):e1–4. - Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natali-
zumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler.
2015;21(2):198–205. - Dubinsky M, Mahadevan U, Vermeire S, et al. Vedolizumab exposure in pregnancy: outcomes
from clinical studies in inflammatory bowel disease. ECCO. 2015. p. 563. - Description from FDA NDA review document. http://www.accessdata.fda.gov/drugsatfda_
docs/nda/2009/125261s000_OtherR.pdf. - Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following admin-
istration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody during pregnancy
and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–63. - Data on file. Reports of pregnancy with ustekinumab: STE/Inj/DoF/Sep2010/EMEA001.
2010. Janssen. Available from: http://www.stelarahcp.com, accessed on July 4, 2017. - Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontanous abortion during ustekinumab
therapy. J Dermatol Case Rep. 2012;6(4):105–7. - Rocha K, Piccinin MC, Kalache L, et al. Pregnancy during ustekinumab treatment for severe
psoriasis. Dermatology. 2015;231:103–4. - Adrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy.
J Drugs Dermatol. 2012;11(10):1240–1. - Alsenaid A, Prinz JC. Inadvertant pregnancy during ustekinumab therapy in a patient with
plaque psoriasis and impetigo herpetiformis. JEADV. 2016;30:488–90. - Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the
first trimester. Australas J Dermatol. 2014;55:235–6. - Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for
use of antirheumatic drugs before pregnancy, during pregnancy and lactation. Ann Rheum Dis.
2016;75:795–810. - Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol.
2008;14(19):3085–7. - Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from
nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin
Gastroenterol. 2009;43:613–6. - Ben-Horin S, Yovzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing
mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555–8. - Grosen A, Julsgaard M, Kelsen J, Christensen LA. Infliximab concentrations in the milk of
nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2014;8:175–6. - Ben-Horin S, Yovzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother.
Clin Gastroenterol Hepatol. 2010;8:475–6. - Fritzsche J, Pilch A, Mury D, et al. Infliximab and adalimumab use during breastfeeding.
J Clin Gastroenterol. 2012;46:718–9. - Martin PL, Oneda S, Treacy G. Effects of an anti-TNFa monoclonal antibody, administered
throughout pregnancy and lactation, on the development of the macaque immune system. Am
J Reprod Immunol. 2007;58:138–49. - Natalizumab (Tysabri) package insert. Cambridge: Biogen Inc. 2004. Available from: http://
http://www.avonex.com. - Vedolizumab (Entyvio) package insert. Cambridge: Takeda. 2014. Available from: http://
http://www.general.takedapharm.com.
6 Biologics in Pregnancy and Breastfeeding